Desvenlafaxine

Sun Pharma Global FZE

HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use DESVENLAFAXINE safely and effectively. See full prescribing information for DESVENLAFAXINEDESVENLAFAXINE extended-release tablets, for oral useInitial U.S. Approval: 2008BOXED WARNING WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning . Increased risk of suicidal thinking and behavior in children, adolescents and young adults taking antidepressants ( 5.1 ). Monitor for worsening and emergence of suicidal thoughts and behaviors ( 5.1 ). Desvenlafaxine extended-release tablets are not approved for use in pediatric patients ( 8.4 ). INDICATIONS AND USAGEDesvenlafaxine, a serotonin and norepinephrine reuptake inhibitor (SNRI), are indicated for the treatment of major depressive disorder (MDD) (1).DOSAGE AND ADMINISTRATION Recommended dose: 50 mg once daily with or without food (2.1). There was no evidence that doses greater than 50 mg per day confer any additional benefit (2.1). Discontinuation: Reduce dose gradually whenever possible (2.1). Take tablets whole; do not divide, crush, chew, or dissolve (2.1). Moderate renal impairment: Maximum dose is 50 mg per day (2.2). Severe renal impairment and end-stage renal disease (ESRD): Maximum dose is 50 mg every other day (2.2). Moderate to severe hepatic impairment: Maximum dose is 100 mg per day (2.2). DOSAGE FORMS AND STRENGTHS Desvenlafaxine Extended-Release Tablets are available as 50 mg and 100 mg  (3). Each tablet contains 72 mg or 144 mg of desvenlafaxine fumarate equivalent to 50 mg or 100 mg of desvenlafaxine (3). CONTRAINDICATIONS Hypersensitivity to desvenlafaxine fumarate, venlafaxine hydrochloride or any excipients in the desvenlafaxine extended-release tablet formulation (4). Serotonin syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders concomitantly with desvenlafaxine extended-release tablets or within 7 days of stopping treatment with desvenlafaxine extended-release tablets. Do not use desvenlafaxine extended release tablets within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start desvenlafaxine extended release tablets in a patient who is being treated with linezolid or intravenous methylene blue (4). WARNINGS AND PRECAUTIONS Serotonin Syndrome: Serotonin syndrome has been reported with SSRIs and SNRIs, including desvenlafaxine extended-release tablets, both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort). If such symptoms occur, discontinue desvenlafaxine extended-release tablets and initiate supportive treatment. If concomitant use of desvenlafaxine extended-release tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases (5.2). Elevated Blood Pressure: Control hypertension before initiating treatment. Monitor blood pressure regularly during treatment (5.3). Abnormal Bleeding: Desvenlafaxine extended-release tablets may increase risk of bleeding events. Caution patients about risk of bleeding associated with concomitant use of desvenlafaxine extended-release tablets and NSAIDs, aspirin, or other drugs that affect coagulation (5.4). Narrow-angle Glaucoma: Mydriasis has occurred with desvenlafaxine extended-release tablets. Monitor patients with raised intraocular pressure or those at risk of angle-closure glaucoma (5.5). Activation of Mania/Hypomania: Use cautiously in patients with Bipolar Disorder. Caution patients about the risk of activation of mania/hypomania (5.6). Discontinuation Syndrome: Taper dose when possible and monitor for discontinuation symptoms (5.7). Seizure: Can occur. Use cautiously in patients with seizure disorder (5.8). Hyponatremia: Can occur in association with SIADH (5.9). Interstitial Lung Disease and Eosinophilic Pneumonia: Can occur (5.10). Side EffectsMost common adverse reactions (incidence ≥ 5% and twice the rate of placebo in the 50 mg or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders (6.1). To report SUSPECTED ADVERSE REACTIONS, contact CARACO Pharmaceutical Laboratories, Ltd. at 1- 800-818-4555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch USE IN SPECIFIC POPULATIONS Pregnancy: Based on animal data, may cause fetal harm. (8.1). Nursing Mothers: Discontinue drug or nursing taking into consideration importance of drug to mother (8.3). Geriatric Use: There is an increased incidence of orthostatic hypotension in patients ≥ 65 years treated with desvenlafaxine extended-release tablet (6.1 and 8.5).

FULL PRESCRIBING INFORMATION: CONTENTS*

• WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
• 1 DESVENLAFAXINE INDICATIONS AND USAGE
• 2 DESVENLAFAXINE DOSAGE AND ADMINISTRATION
  • 2.1 General Instruction for Use
  • 2.2 Special Populations
  • 2.3 Maintenance/Continuation/Extended Treatment
  • 2.4 Discontinuing Desvenlafaxine Extended-Release Tablets
  • 2.5 Switching Patients From Other Antidepressants to Desvenlafaxine Extended-Release Tablets
  • 2.6 Switching Patients To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders
• 3 DOSAGE FORMS AND STRENGTHS
• 4 DESVENLAFAXINE CONTRAINDICATIONS
• 5 WARNINGS AND PRECAUTIONS
  • 5.1 Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults
  • 5.2 Serotonin Syndrome
  • 5.3 Elevated Blood Pressure
  • 5.4 Abnormal Bleeding
  • 5.5 Narrow-Angle Glaucoma
  • 5.6 Activation of Mania/Hypomania
  • 5.7 Discontinuation Syndrome
  • 5.8 Seizure
  • 5.9 Hyponatremia
  • 5.10 Interstitial Lung Disease and Eosinophilic Pneumonia
• 6 DESVENLAFAXINE ADVERSE REACTIONS
  • 6.1 Clinical Studies Experience
  • 6.2 Postmarketing Experience
• 7 DRUG INTERACTIONS
  • 7.1 Monoamine Oxidase Inhibitors (MAOI)
  • 7.2 Serotonergic Drugs
  • 7.3 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin)
  • 7.4 Potential for Other Drugs to Affect Desvenlafaxine
  • 7.5 Potential for Desvenlafaxine to Affect Other Drugs
  • 7.6 Other Drugs Containing Desvenlafaxine or Venlafaxine
  • 7.7 Ethanol
  • 7.8 Drug-Laboratory Test Interactions
• 8 USE IN SPECIFIC POPULATIONS
  • 8.1 Pregnancy
  • 8.3 Nursing Mothers
  • 8.4 Pediatric Use
  • 8.5 Geriatric Use
  • 8.6 Other Patient Factors
• 9 DRUG ABUSE AND DEPENDENCE
  • 9.1 Controlled Substance
• 10 OVERDOSAGE
  • 10.1 Human Experience with Overdosage
  • 10.2 Management of Overdosage
• 11 DESVENLAFAXINE DESCRIPTION
• 12 CLINICAL PHARMACOLOGY
  • 12.1 Mechanism of Action
  • 12.2 Pharmacodynamics
  • 12.3 Pharmacokinetics
• 13 NONCLINICAL TOXICOLOGY
  • 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
• 14 CLINICAL STUDIES
• 16 HOW SUPPLIED/STORAGE AND HANDLING
• 17 PATIENT COUNSELING INFORMATION
• MEDICATION GUIDE
• PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Desvenlafaxine extended-release tablets, a serotonin and norepinephrine reuptake inhibitor (SNRI), are indicated for the treatment of major depressive disorder (MDD) [see Clinical Studies ( 14 ) and Dosage and Administration ( 2.1 )]. The efficacy of desvenlafaxine extended-release tablets has been established in four short-term (8-week, placebo-controlled studies) in adult outpatients who met DSM-IV criteria for major depressive disorder.

2 DOSAGE AND ADMINISTRATION

2.1 General Instruction for Use

The recommended dose for desvenlafaxine extended-release tablets is 50 mg once daily, with or without food.
In clinical studies, doses of 50 mg to 400 mg per day were shown to be effective, although no additional benefit was demonstrated at doses greater than 50 mg per day, and adverse reactions and discontinuations were more frequent at higher doses.
When discontinuing therapy, gradual dose reduction is recommended whenever possible to minimize discontinuation symptoms [see Dosage and Administration (2.4) and Warnings and Precautions (5.7)].
Desvenlafaxine extended-release tablets should be taken at approximately the same time each day. Tablets must be swallowed whole with fluid and not divided, crushed, chewed, or dissolved.

2.2 Special Populations

Patients with Renal Impairment  
The maximum recommended dose in patients with moderate renal impairment (24-hr creatinine clearance [CrCl] = 30 to 50 mL/min, Cockcroft-Gault [C-G]) is 50 mg per day. The maximum recommended dose in patients with severe renal impairment (24-hr CrCl less than 30 mL/min, C-G) or end-stage renal disease (ESRD) is 50 mg every other day. Supplemental doses should not be given to patients after dialysis [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].
Patients with Hepatic Impairment
The recommended dose in patients with moderate to severe hepatic impairment is 50 mg per day. Dose escalation above 100 mg per day is not recommended [see Clinical Pharmacology (12.3)].

2.3 Maintenance/Continuation/Extended Treatment

It is generally agreed that acute episodes of major depressive disorder require several months or longer of sustained pharmacologic therapy. Patients should be periodically reassessed to determine the need for continued treatment.

2.4 Discontinuing Desvenlafaxine Extended-Release Tablets

Symptoms associated with discontinuation of desvenlafaxine extended-release tablets, other SNRIs and SSRIs have been reported [see Warnings and Precautions (5.7)]. Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.

2.5 Switching Patients From Other Antidepressants to Desvenlafaxine Extended-Release Tablets

Discontinuation symptoms have been reported when switching patients from other antidepressants, including venlafaxine, to desvenlafaxine extended-release tablets. Tapering of the initial antidepressant may be necessary to minimize discontinuation symptoms.

2.6 Switching Patients To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders

At least 14 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with desvenlafaxine extended-release tablets. Conversely, at least 7 days should be allowed after stopping desvenlafaxine extended-release tablets before starting an MAOI intended to treat psychiatric disorders [see Contraindications (4)].

Use of Desvenlafaxine Extended-Release Tablets with other MAOIs such as Linezolid or Methylene Blue
Do not start desvenlafaxine extended-release tablets in a patient who is being treated with linezolid or intravenous methylene blue because there is increased risk of serotonin syndrome. In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered [see Contraindications (4)].
In some cases, a patient already receiving desvenlafaxine extended-release tablet therapy may require urgent treatment with linezolid or intravenous methylene blue. If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, desvenlafaxine extended-release tablets should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome for 7 days or until 24 hours after the last dose of linezolid or intravenous methylene blue, whichever comes first. Therapy with desvenlafaxine extended-release tablets may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue [see Warnings and Precautions (5.2)].
The risk of administering methylene blue by non-intravenous routes (such as oral tablets or by local injection) or in intravenous doses much lower than 1 mg/kg with desvenlafaxine extended-release tablets is unclear. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of serotonin syndrome with such use [see Warnings and Precautions (5.2)].

3 DOSAGE FORMS AND STRENGTHS

Desvenlafaxine extended-release tablets are available as:

50 mg, light-pink, circular, biconvex, beveled edge, film-coated tablets, imprinted with '747' in black ink on one side and plain on the other side.
100 mg, brick red, circular biconvex, beveled edge, film-coated tablets, imprinted with '804' in black ink on one side and plain on the other side.

4 CONTRAINDICATIONS

• Hypersensitivity to desvenlafaxine fumarate, venlafaxine hydrochloride or to any excipients in the desvenlafaxine extended-release tablet formulation. Angioedema has been reported in patients treated with desvenlafaxine extended-release tablets [see Adverse Reactions (6.1)].
• The use of MAOIs intended to treat psychiatric disorders with desvenlafaxine extended-release tablets or within 7 days of stopping treatment with desvenlafaxine extended-release tablets is contraindicated because of an increased risk of serotonin syndrome. The use of desvenlafaxine extended-release tablets within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated [see Dosage and Administration (2.6) and Warnings and Precautions (5.2)].

Starting desvenlafaxine extended-release tablets in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see Dosage and Administration (2.6) and Warnings and Precautions (5.2)].

5 WARNINGS AND PRECAUTIONS

5.1 Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults

Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short-term placebo-controlled studies of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with major depressive disorder (MDD) and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.

The pooled analyses of placebo-controlled studies in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term studies of 9 antidepressant drugs in over 4,400 patients. The pooled analyses of placebo-controlled studies in adults with MDD or other psychiatric disorders included a total of 295 short-term studies (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drug-placebo difference in the number of cases of suicidality per 1000 patients treated) are provided in Table 1.

No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about drug effect on suicide.

It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance studies in adults with depression that the use of antidepressants can delay the recurrence of depression.

All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.

The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality.

Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.

If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms [see Dosage and Administration (2.4) and Warnings and Precautions (5.7)].

Families and caregivers of patients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to healthcare providers. Such monitoring should include daily observation by families and caregivers.

Prescriptions for desvenlafaxine extended-release tablets should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose.

Screening patients for bipolar disorder
A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled studies) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that desvenlafaxine extended-release tablets are not approved for use in treating bipolar depression.

5.2 Serotonin Syndrome

The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including desvenlafaxine extended-release tablets, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort), and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome.

The concomitant use of desvenlafaxine extended-release tablets with MAOIs intended to treat psychiatric disorders is contraindicated. Desvenlafaxine extended-release tablets should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with a MAOI such as linezolid or intravenous methylene blue in a patient taking desvenlafaxine extended-release tablets. Desvenlafaxine extended-release tablets should be discontinued before initiating treatment with the MAOI [see Contraindications (4) and Dosage and Administration (2.6)].

If concomitant use of desvenlafaxine extended-release tablets with other serotonergic drugs, including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John's Wort is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases.

Treatment with desvenlafaxine extended-release tablets and any concomitant serotonergic agents should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.

5.3 Elevated Blood Pressure

Patients receiving desvenlafaxine extended-release tablets should have regular monitoring of blood pressure since increases in blood pressure were observed in clinical studies [see Adverse Reactions (6.1)]. Pre-existing hypertension should be controlled before initiating treatment with desvenlafaxine extended-release tablets. Caution should be exercised in treating patients with pre-existing hypertension, cardiovascular, or cerebrovascular conditions that might be compromised by increases in blood pressure. Cases of elevated blood pressure requiring immediate treatment have been reported with desvenlafaxine extended-release tablets.

Sustained blood pressure increases could have adverse consequences. For patients who experience a sustained increase in blood pressure while receiving desvenlafaxine extended-release tablets, either dose reduction or discontinuation should be considered [see Adverse Reactions (6.1)].

5.4 Abnormal Bleeding

SSRIs and SNRIs, including desvenlafaxine extended-release tablets, may increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs, warfarin, and other anticoagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Bleeding events related to SSRIs and SNRIs have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages. Patients should be cautioned about the risk of bleeding associated with the concomitant use of desvenlafaxine extended-release tablets and NSAIDs, aspirin, or other drugs that affect coagulation or bleeding.

5.5 Narrow-Angle Glaucoma

Mydriasis has been reported in association with desvenlafaxine extended-release tablets; therefore, patients with raised intraocular pressure or those at risk of acute narrow-angle glaucoma (angle-closure glaucoma) should be monitored.

5.6 Activation of Mania/Hypomania

During all MDD phase 2 and phase 3 studies, mania was reported for approximately 0.02% of patients treated with desvenlafaxine extended-release tablets. Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorder who were treated with other marketed antidepressants. As with all antidepressants, desvenlafaxine extended-release tablets should be used cautiously in patients with a history or family history of mania or hypomania.

5.7 Discontinuation Syndrome

Discontinuation symptoms have been systematically and prospectively evaluated in patients treated with desvenlafaxine extended-release tablets during clinical studies in Major Depressive Disorder. Abrupt discontinuation or dose reduction has been associated with the appearance of new symptoms that include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, fatigue, abnormal dreams, and hyperhidrosis. In general, discontinuation events occurred more frequently with longer duration of therapy.

During marketing of SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRIs (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesia, such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms. 

Patients should be monitored for these symptoms when discontinuing treatment with desvenlafaxine extended-release tablets. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate [see Dosage and Administration (2.4) and Adverse Reactions (6.1)].

5.8 Seizure

Cases of seizure have been reported in pre-marketing clinical studies with desvenlafaxine extended-release tablets. Desvenlafaxine extended-release tablets have not been systematically evaluated in patients with a seizure disorder. Patients with a history of seizures were excluded from pre-marketing clinical studies. Desvenlafaxine extended-release tablets should be prescribed with caution in patients with a seizure disorder.

5.9 Hyponatremia

Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including desvenlafaxine extended-release tablets. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Cases with serum sodium lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.3)]. Discontinuation of desvenlafaxine extended-release tablets should be considered in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted.

Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.

5.10 Interstitial Lung Disease and Eosinophilic Pneumonia

Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine (the parent drug of desvenlafaxine extended-release tablets) therapy have been rarely reported. The possibility of these adverse events should be considered in patients treated with desvenlafaxine extended-release tablets who present with progressive dyspnea, cough, or chest discomfort. Such patients should undergo a prompt medical evaluation, and discontinuation of desvenlafaxine extended-release tablets should be considered.

6 ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of the label.

• Hypersensitivity [see Contraindications (4)]
• Suicidal Thoughts and Behaviors in Children, Adolescents and Young Adults [see Warnings and Precautions (5.1)]
• Serotonin Syndrome [see Warnings and Precautions (5.2)]
• Elevated Blood Pressure [see Warnings and Precautions (5.3)]
• Abnormal Bleeding [see Warnings and Precautions (5.4)]
• Narrow-Angle Glaucoma [see Warnings and Precautions (5.5)]
• Activation of Mania/Hypomania [see Warnings and Precautions (5.6)]
• Discontinuation Syndrome [see Warnings and Precautions (5.7)]
• Seizure [see Warnings and Precautions (5.8)]
• Hyponatremia [see Warnings and Precautions (5.9)]
• Interstitial Lung Disease and Eosinophilic Pneumonia [see Warnings and Precautions (5.10)]

6.1 Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.


Patient exposure
Desvenlafaxine extended-release tablets were evaluated for safety in 8,394 patients diagnosed with major depressive disorder who participated in multiple-dose pre-marketing studies, representing 2,784 patient-years of exposure. Of the total 8,394 patients exposed to at least one dose of desvenlafaxine extended-release tablets; 2,116 were exposed to desvenlafaxine extended-release tablets for 6 months, representing 1,658 patient-years of exposure, and 421 were exposed for one year, representing 416 patient-years of exposure.


Adverse reactions reported as reasons for discontinuation of treatment

In the pre-marketing pooled 8-week placebo-controlled studies in patients with MDD, 1,834 patients were exposed to desvenlafaxine extended-release tablets (50 mg to 400 mg). Of the 1,834 patients, 12% discontinued treatment due to an adverse reaction, compared with 3% of the 1,116 placebo-treated patients. At the recommended dose of 50 mg, the discontinuation rate due to an adverse reaction for desvenlafaxine extended-release tablets (4.1%) was similar to the rate for placebo (3.8%). For the 100 mg dose of desvenlafaxine extended-release tablets the discontinuation rate due to an adverse reaction was 8.7%.

The most common adverse reactions leading to discontinuation in at least 2% and at a rate greater than placebo of the desvenlafaxine extended-release tablet treated patients in the short-term studies, up to 8 weeks, were: nausea (4%); dizziness, headache and vomiting (2% each). In a longer-term study, up to 9 months, the most common was vomiting (2%).


Common adverse reactions in placebo-controlled MDD studies
The most commonly observed adverse reactions in desvenlafaxine extended-release tablet treated MDD patients in pre-marketing pooled 8-week, placebo-controlled, fixed-dose studies (incidence ≥ 5% and at least twice the rate of placebo in the 50 or 100 mg dose groups) were: nausea, dizziness, insomnia, hyperhidrosis, constipation, somnolence, decreased appetite, anxiety, and specific male sexual function disorders.


Table 2 shows the incidence of common adverse reactions that occurred in ≥ 2% of desvenlafaxine extended-release tablet treated MDD patients and twice the rate of placebo at any dose in the pre-marketing pooled 8-week, placebo-controlled, fixed dose clinical studies

Sexual function adverse reactions

Table 3 shows the incidence of sexual function adverse reactions that occurred in ≥ 2% of desvenlafaxine extended-release tablet treated MDD patients in any fixed-dose group (pre-marketing pooled 8-week, placebo-controlled, fixed -dose, clinical studies).

Other adverse reactions observed in premarketing and postmarketing clinical studies
Other infrequent adverse reactions, not described elsewhere in the label, occurring at an incidence of < 2% in MDD patients treated with desvenlafaxine extended-release tablets were: 

Cardiac disorders – tachycardia.
General disorders and administration site conditions – Asthenia
Investigations – Weight increased, liver function test abnormal, blood prolactin increased.
Musculoskeletal and connective tissue disorders – Musculoskeletal stiffness.
Nervous system disorders – Syncope, convulsion, dystonia.
Psychiatric disorders – Depersonalization, bruxism.
Renal and urinary disorders – Urinary retention.
Skin and subcutaneous tissue disorders – Rash, alopecia, photosensitivity reaction, angioedema.


In clinical studies, there were uncommon reports of ischemic cardiac adverse reactions, including myocardial ischemia, myocardial infarction, and coronary occlusion requiring revascularization; these patients had multiple underlying cardiac risk factors. More patients experienced these events during desvenlafaxine extended-release tablet treatment as compared to placebo.


Laboratory, ECG and vital sign changes observed in MDD clinical studies
The following changes were observed in pre-marketing placebo-controlled, short-term MDD studies with desvenlafaxine extended-release tablets.


Lipids
Elevations in fasting serum total cholesterol, LDL (low density lipoproteins) cholesterol, and triglycerides occurred in the controlled studies. Some of these abnormalities were considered potentially clinically significant. 

The percentage of patients who exceeded a predetermined threshold value is shown in Table 4.

Proteinuria
Proteinuria, greater than or equal to trace, was observed in the pre-marketing fixed-dose controlled studies (see Table 5). This proteinuria was not associated with increases in BUN or creatinine and was generally transient.

Vital sign changes
Table 6 summarizes the changes that were observed in placebo-controlled, short-term, pre-marketing studies with desvenlafaxine extended-release tablets in patients with MDD (doses 50 to 400 mg).

Treatment with desvenlafaxine extended-release tablets at all doses from 50 mg/day to 400 mg/day in controlled studies was associated with sustained hypertension, defined as treatment-emergent supine diastolic blood pressure (SDBP) ≥ 90 mm Hg and ≥ 10 mm Hg above baseline for 3 consecutive on-therapy visits (see Table 7). Analyses of patients in desvenlafaxine extended-release tablets pre-marketing short-term controlled studies who met criteria for sustained hypertension revealed a consistent increase in the proportion of patients who developed sustained hypertension. This was seen at all doses with a suggestion of a higher rate at 400 mg/day.

Orthostatic hypotension
In the pre-marketing short-term, placebo-controlled clinical studies with doses of 50 to 400 mg, systolic orthostatic hypotension (decrease ≥ 30 mm Hg from supine to standing position) occurred more frequently in patients ≥ 65 years of age receiving desvenlafaxine extended-release tablets (8%, 7/87) versus placebo (2.5%, 1/40), compared to patients < 65 years of age receiving desvenlafaxine extended-release tablets (0.9%, 18/1,937) versus placebo (0.7%, 8/1,218).

6.2 Postmarketing Experience

The following adverse reaction has been identified during post-approval use of desvenlafaxine extended-release tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:

Skin and subcutaneous tissue disorders – Stevens-Johnson syndrome.

7 DRUG INTERACTIONS

7.1 Monoamine Oxidase Inhibitors (MAOI)

Do not use MAOIs intended to treat psychiatric disorders concomitantly with desvenlafaxine or within 7 days of stopping treatment with desvenlafaxine. Do not use desvenlafaxine within 14 days of stopping an MAOI intended to treat psychiatric disorders. In addition, do not start desvenlafaxine in a patient who is being treated with linezolid or intravenous methylene blue [see Dosage and Administration (2.6), Contraindications (4) and Warnings and Precautions (5.2)].

7.2 Serotonergic Drugs

Based on the mechanism of action of desvenlafaxine extended-release tablets and the potential for serotonin syndrome, caution is advised when desvenlafaxine extended-release tablets are co-administered with other drugs that may affect the serotonergic neurotransmitter systems [see Dosage and Administration (2.6), Contraindications (4) and Warnings and Precautions (5.2)]

7.3 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin)

Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding. These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs and SNRIs are coadministered with warfarin. Patients receiving warfarin therapy should be carefully monitored when desvenlafaxine extended-release tablets are initiated or discontinued [see Warnings and Precautions (5.4)].

7.4 Potential for Other Drugs to Affect Desvenlafaxine

Based on in vitro data, no dose adjustment is required for desvenlafaxine extended-release tablets when used concomitantly with inhibitors of CYP3A4 and CYP1A1, 1A2, 2A6, 2D6, 2C8, 2C9, 2C19, 2E1, and the P-glycoprotein transporter. Clinical studies have demonstrated no clinically significant pharmacokinetic interaction between desvenlafaxine and strong CYP3A4 inhibitors (Figure 1).

7.5 Potential for Desvenlafaxine to Affect Other Drugs

Clinical studies have shown that desvenlafaxine does not have a clinically relevant effect on CYP2D6 metabolism at the dose of 100 mg daily (Figure 2). Substrates primarily metabolized by CYP2D6 (e.g., desipramine, atomoxetine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine) should be dosed at the original level when coadministered with desvenlafaxine extended-release tablets 100 mg or lower. Reduce the dose of these substrates by one-half if coadministered with 400 mg of desvenlafaxine extended-release tablets.
No additional dose adjustment is required for concomitant use of substrates of CYP3A4, 1A2, 2A6, 2C8, 2C9, and 2C19 isozymes, and P-glycoprotein transporter. Clinical studies have demonstrated no clinically significant pharmacokinetic interaction between desvenlafaxine extended-release tablets and CYP3A4 substrates (Figure 2).
Clinical studies have shown that desvenlafaxine (100 mg daily) does not have a clinically relevant effect on tamoxifen and aripiprazole, compounds that are metabolized by a combination of both CYP2D6 and CYP3A4 enzymes (Figure 2).
In vitro studies showed minimal inhibitory effect of desvenlafaxine on the CYP2D6 isoenzyme.
In vitro, desvenlafaxine does not inhibit or induce the CYP3A4 isozyme.
In vitro, desvenlafaxine does not inhibit CYP1A2, 2A6, 2C8, 2C9, and 2C19 isozymes; and the P-glycoprotein transporter and would not be expected to affect the pharmacokinetics of drugs that are substrates of these CYP isozymes and transporter.

7.6 Other Drugs Containing Desvenlafaxine or Venlafaxine

Avoid use of desvenlafaxine extended-release tablets with other desvenlafaxine-containing products or venlafaxine products. The concomitant use of desvenlafaxine extended-release tablets with other desvenlafaxine-containing products or venlafaxine will increase desvenlafaxine blood levels and increase dose-related adverse reactions [see Adverse Reactions (6)].

7.7 Ethanol

A clinical study has shown that desvenlafaxine extended-release tablets do not increase the impairment of mental and motor skills caused by ethanol. However, as with all CNS-active drugs, patients should be advised to avoid alcohol consumption while taking desvenlafaxine extended-release tablets.

7.8 Drug-Laboratory Test Interactions

False positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been reported in patients taking desvenlafaxine. This is due to lack of specificity of the screening tests. False positive results may be expected for several days following discontinuation of desvenlafaxine therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish desvenlafaxine from PCP and amphetamine.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C
Risk summary
There are no adequate and well-controlled studies of desvenlafaxine extended-release tablets in pregnant women. In reproductive developmental studies in rats and rabbits with desvenlafaxine succinate, evidence of teratogenicity was not observed at doses up to 30 times a human dose of 100 mg/day (on a mg/m² basis) in rats, and up to 15 times a human dose of 100 mg/day (on a mg/m² basis) in rabbits. An increase in rat pup deaths was seen during the first 4 days of lactation when dosing occurred during gestation and lactation, at doses greater than 10 times a human dose of 100 mg/day (on a mg/m² basis). Desvenlafaxine extended-release tablets should be used during pregnancy only if the potential benefits justify the potential risks to the fetus.

Clinical considerations
A prospective longitudinal study of 201 women with history of major depression who were euthymic at the beginning of pregnancy, showed women who discontinued antidepressant medication during pregnancy were more likely to experience a relapse of major depression than women who continued antidepressant medication.

Human data
Neonates exposed to SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), or SSRIs (Selective Serotonin Reuptake Inhibitors), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome [see Warnings and Precautions (5.2)].

Animal data
When desvenlafaxine succinate was administered orally to pregnant rats and rabbits during the period of organogenesis at doses up to 300 mg/kg/day and 75 mg/kg/day, respectively, no teratogenic effects were observed. These doses are 30 times a human dose of 100 mg/day (on a mg/m² basis) in rats and 15 times a human dose of 100 mg/day (on a mg/m² basis) in rabbits. However, fetal weights were decreased and skeletal ossification was delayed in rats in association with maternal toxicity at the highest dose, with a no-effect dose 10 times a human dose of 100 mg/day (on a mg/m² basis).

When desvenlafaxine succinate was administered orally to pregnant rats throughout gestation and lactation, there was a decrease in pup weights and an increase in pup deaths during the first four days of lactation at the highest dose of 300 mg/kg/day. The cause of these deaths is not known. The no-effect dose for rat pup mortality was 10 times a human dose of 100 mg/day (on a mg/m² basis). Post-weaning growth and reproductive performance of the progeny were not affected by maternal treatment with desvenlafaxine succinate at a dose 30 times a human dose of 100 mg/day (on a mg/m² basis).

8.3 Nursing Mothers

Desvenlafaxine (O-desmethylvenlafaxine) is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from desvenlafaxine extended-release tablets, a decision should be made whether or not to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

8.4 Pediatric Use

Safety and effectiveness in the pediatric population have not been established [see Boxed Warning  and Warnings and Precautions ( 5.1 )]. Anyone considering the use of desvenlafaxine extended-release tablets in a child or adolescent must balance the potential risks with the clinical need.

8.5 Geriatric Use

Of the 4,158 patients in pre-marketing clinical studies with desvenlafaxine extended-release tablets, 6% were 65 years of age or older. No overall differences in safety or efficacy were observed between these patients and younger patients; however, in the short-term, placebo-controlled studies, there was a higher incidence of systolic orthostatic hypotension in patients ≥ 65 years of age compared to patients < 65 years of age treated with desvenlafaxine extended-release tablets [see Adverse Reactions ( 6 )]. For elderly patients, possible reduced renal clearance of desvenlafaxine should be considered when determining dose [see Dosage and Administration ( 2.2 ) and Clinical Pharmacology ( 12.3 )].

SSRIs and SNRIs, including desvenlafaxine extended-release tablets, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event [see Warnings and Precautions (5.9)].

8.6 Other Patient Factors

The effect of intrinsic patient factors on the pharmacokinetics of desvenlafaxine is presented in Figure 3.

Renal Impairment 
In subjects with renal impairment, the clearance of desvenlafaxine extended-release tablets was decreased. In subjects with severe renal impairment (24-hr CrCl < 30 mL/min, Cockcroft-Gault) and end-stage renal disease, elimination half-lives were significantly prolonged, increasing exposures of desvenlafaxine extended-release tablets; therefore, dosage adjustment is recommended in these patients [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)]. 

Hepatic Impairment 
The mean terminal half life (t_1/2) changed from approximately 10 hours in healthy subjects and subjects with mild hepatic impairment to 13 and 14 hours in moderate and severe hepatic impairment, respectively. The recommended dose in patients with moderate to severe hepatic impairment is 50 mg per day. Dose escalation above 100 mg per day is not recommended [see Clinical Pharmacology (12.3)].

9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

Desvenlafaxine extended-release tablets are not a controlled substance.

10 OVERDOSAGE

10.1 Human Experience with Overdosage

There is limited clinical trial experience with desvenlafaxine succinate overdosage in humans. However, desvenlafaxine is the major active metabolite of venlafaxine. Overdose experience reported with venlafaxine (the parent drug of desvenlafaxine) is presented below; the identical information can be found in the Overdosage section of the venlafaxine package insert.

In postmarketing experience, overdose with venlafaxine (the parent drug of desvenlafaxine) has occurred predominantly in combination with alcohol and/or other drugs. The most commonly reported events in overdosage include tachycardia, changes in level of consciousness (ranging from somnolence to coma), mydriasis, seizures, and vomiting. Electrocardiogram changes (e.g., prolongation of QT interval, bundle branch block, QRS prolongation), sinus and ventricular tachycardia, bradycardia, hypotension, rhabdomyolysis, vertigo, liver necrosis, serotonin syndrome, and death have been reported.

Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants. Epidemiological studies have shown that venlafaxine-treated patients have a higher pre-existing burden of suicide risk factors than SSRI-treated patients. The extent to which the finding of an increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in overdosage, as opposed to some characteristic(s) of venlafaxine-treated patients, is not clear.

10.2 Management of Overdosage

No specific antidotes for desvenlafaxine extended-release tablets are known. In managing over dosage, consider the possibility of multiple drug involvement. In case of overdose, call Poison Control Center at 1-800-222-1222 for latest recommendations.

11 DESCRIPTION

Desvenlafaxine extended-release tablets for oral administration contain desvenlafaxine fumarate, a SNRI for the treatment of MDD. Desvenlafaxine (O-desmethylvenlafaxine) is the major active metabolite of the antidepressant venlafaxine, a medication used to treat major depressive disorders.

Desvenlafaxine is designated RS-4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol and has the molecular formula of C₁₆H₂₅NO₂ (free base) and C₁₆H₂₅NO₂•C₄H₄O₄•H₂O (fumarate monohydrate). Desvenlafaxine fumarate monohydrate has a molecular weight of 397.45. The structural formula is shown below.

Desvenlafaxine fumarate is a white to off-white powder that is slightly soluble in water and soluble in methanol. The solubility of desvenlafaxine fumarate is pH dependent. Its octanol:aqueous system (at pH 7) partition coefficient is 0.21.

Desvenlafaxine fumarate, as a base, is formulated as an extended-release tablet for once-a-day oral administration.
Each tablet contains 72 mg or 144 mg of desvenlafaxine fumarate equivalent to 50 mg or 100 mg of desvenlafaxine, respectively.

Inactive ingredients for the 50 mg tablet consist of microcrystalline cellulose, hypromellose, magnesium stearate, talc, colloidal silicon dioxide, ferric oxide red and film-coating which contains hypromellose, titanium dioxide, polyethylene glycol, talc, iron oxide red and iron oxide yellow.

Inactive ingredients for the 100 mg tablet consist of microcrystalline cellulose, hypromellose, magnesium stearate, talc, colloidal silicon dioxide and film-coating which contain hypromellose, titanium dioxide, polyethylene glycol, talc, iron oxide red and iron oxide yellow.

The imprinting ink contains shellac, black iron oxide, n-butyl alcohol, propylene glycol and ammonium hydroxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The exact mechanism of the antidepressant action of desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. Non-clinical studies have shown that desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI).

12.2 Pharmacodynamics

Desvenlafaxine lacked significant affinity for numerous receptors, including muscarinic-cholinergic, H₁-histaminergic, or α₁-adrenergic receptors in vitro. Desvenlafaxine also lacked monoamine oxidase (MAO) inhibitory activity.

ECG changes
Electrocardiograms were obtained from 1,492 desvenlafaxine treated patients with major depressive disorder and 984 placebo-treated patients in clinical studies lasting up to 8 weeks. No clinically relevant differences were observed between desvenlafaxine treated and placebo-treated patients for QT, QTc, PR, and QRS intervals. In a thorough QTc study with prospectively determined criteria, desvenlafaxine did not cause QT prolongation. No difference was observed between placebo and desvenlafaxine treatments for the QRS interval.

12.3 Pharmacokinetics

The single-dose pharmacokinetics of desvenlafaxine are linear and dose-proportional in a dose range of 50 to 600 mg/day. With once-daily dosing, steady-state plasma concentrations are achieved within approximately 4 to 5 days. At steady-state, multiple-dose accumulation of desvenlafaxine is linear and predictable from the single-dose pharmacokinetic profile.

The mean terminal half-life, t_1/2, of desvenlafaxine after administration of this desvenlafaxine extended-release-tablet is about  10 hours. The median (range) time to peak concentration (T_max) is  6 (3  to  16) hours after administration of 50 mg desvenlafaxine extended-release tablets.

Absorption and Distribution
This desvenlafaxine extended-release 50 mg and 100 mg demonstrated similar exposures (C_max, AUC) to a 50 mg and 100 mg extended-release desvenlafaxine succinate product, respectively.

The absolute oral bioavailability of desvenlafaxine succinate extended-release tablets after oral administration is about 80%.

A food-effect study involving administration of this desvenlafaxine extended-release tablets to healthy subjects under fasting and fed conditions (high-fat meal 800 to 1000 calories) indicated that desvenlafaxine C_max was increased about 37% in the fed state, while the AUC was increased about 29% and Tmax increased by about 2.5 hours These differences are not expected to be clinically significant. Desvenlafaxine extended-release tablets can be taken without regard to meals [see Dosage and Administration (2.1)].

The plasma protein binding of desvenlafaxine is low (30%) and is independent of drug concentration. The desvenlafaxine volume of distribution at steady-state following intravenous administration is 3.4 L/kg, indicating distribution into nonvascular compartments.

Metabolism and Elimination
Desvenlafaxine is primarily metabolized by conjugation (mediated by UGT isoforms) and, to a minor extent, through oxidative metabolism. CYP3A4 is the cytochrome P450 isozyme mediating the oxidative metabolism (N-demethylation) of desvenlafaxine. The CYP2D6 metabolic pathway is not involved, and after administration of 100 mg, the pharmacokinetics of desvenlafaxine was similar in subjects with CYP2D6 poor and extensive metabolizer phenotype. Approximately 45% of desvenlafaxine is excreted unchanged in urine at 72 hours after oral administration. Approximately 19% of the administered dose is excreted as the glucuronide metabolite and < 5% as the oxidative metabolite (N,O-didesmethylvenlafaxine) in urine.

Drug Interaction Studies
Inhibitors of CYP3A4 (ketoconazole)
CYP3A4 is a minor pathway for the metabolism of desvenlafaxine. In a clinical study, ketoconazole (200 mg BID) increased the area under the concentration vs. time curve (AUC) of desvenlafaxine (400 mg single dose) by about 43% and C_max by about 8%. Concomitant use of desvenlafaxine with potent inhibitors of CYP3A4 may result in higher concentrations of desvenlafaxine.

Inhibitors of other CYP enzymes
Based on in vitro data, drugs that inhibit CYP isozymes 1A1, 1A2, 2A6, 2D6, 2C8, 2C9, 2C19, and 2E1 are not expected to have significant impact on the pharmacokinetic profile of desvenlafaxine.

Drugs metabolized by CYP2D6 (e.g., desipramine, dextromethorphan, metoprolol, atomoxetine)
In vitro studies showed minimal inhibitory effect of desvenlafaxine on CYP2D6. Clinical studies have shown that desvenlafaxine does not have a clinically relevant effect on CYP2D6 metabolism at the dose of 100 mg daily. When desvenlafaxine succinate was administered at a dose of 100 mg daily in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the C_max and AUC of desipramine increased approximately 25% and 17%, respectively. When 400 mg (8 times the recommended 50 mg dose) was administered, the C_max and AUC of desipramine increased approximately 50% and 90%, respectively. Concomitant use of desvenlafaxine with a drug metabolized by CYP2D6 can result in higher concentrations of that drug [see Drug Interactions (7.4)].

Drugs metabolized by CYP3A4 (midazolam)
In vitro, desvenlafaxine does not inhibit or induce the CYP3A4 isozyme. In a clinical study, desvenlafaxine 400 mg daily (8 times the recommended 50 mg dose) was coadministered with a single 4 mg dose of midazolam (a CYP3A4 substrate). The AUC and C_max of midazolam decreased by approximately 31% and 16%, respectively. Concomitant use of desvenlafaxine with a drug metabolized by CYP3A4 can result in lower exposures to that drug.

Drugs metabolized by CYP1A2, 2A6, 2C8, 2C9 and 2C19
In vitro, desvenlafaxine does not inhibit CYP1A2, 2A6, 2C8, 2C9, and 2C19 isozymes and would not be expected to affect the pharmacokinetics of drugs that are metabolized by these CYP isozymes.

P-glycoprotein
In vitro, desvenlafaxine is not a substrate or an inhibitor for the P-glycoprotein transporter. The pharmacokinetics of desvenlafaxine are unlikely to be affected by drugs that inhibit the P-glycoprotein transporter, and desvenlafaxine is not likely to affect the pharmacokinetics of drugs that are substrates of the P-glycoprotein transporter.

Special Populations
Age
In a study of healthy subjects administered doses of up to 300 mg, there was an approximate 32% increase in C_max and a 55% increase in AUC in subjects older than 75 years of age (n = 17), compared with subjects 18 to 45 years of age (n = 16). Subjects 65 to 75 years of age (n = 15) had no change in C_max, but an approximately 32% increase in AUC, compared to subjects 18 to 45 years of age [see Dosage and Administration (2.2)].

Gender
In a study of healthy subjects administered doses of up to 300 mg, women had an approximately 25% higher C_max and an approximately 10% higher AUC than age-matched men. No adjustment of dosage on the basis of gender is needed.

Race
Pharmacokinetic analysis showed that race (White, n = 466; Black, n = 97; Hispanic, n = 39; Other, n = 33) had no apparent effect on the pharmacokinetics of desvenlafaxine extended-release tablets. No adjustment of dosage on the basis of race is needed.

Hepatic insufficiency
The disposition of desvenlafaxine succinate after administration of 100 mg was studied in subjects with mild (Child-Pugh A, n = 8), moderate (Child-Pugh B, n = 8), and severe (Child-Pugh C, n = 8) hepatic impairment and to healthy subjects (n = 12).

Average AUC was increased by approximately 31% and 35% in patients with moderate and severe hepatic impairment, respectively, as compared to healthy subjects. Average AUC values were similar in subjects with mild hepatic impairment and healthy subjects (< 5% difference).

Systemic clearance (CL/F) was decreased by approximately 20% and 36% in patients with moderate and severe hepatic impairment, respectively, as compared to healthy subjects. CL/F values were comparable in mild hepatic impairment and healthy subjects (< 5% difference).

The mean t_1/2 changed from approximately 10 hours in healthy subjects and subjects with mild hepatic impairment to 13 and 14 hours in moderate and severe hepatic impairment, respectively. The recommended dose in patients with hepatic impairment is 50 mg/day. Dose escalation above 100 mg/day is not recommended [see Use in Specific Populations (8.6)].

Renal insufficiency

The disposition of desvenlafaxine after administration of 100 mg was studied in subjects with mild (n = 9), moderate (n = 8), severe (n = 7) and end-stage renal disease [ESRD] (n = 9) requiring dialysis and in healthy, age-matched control subjects (n = 8). Elimination was significantly correlated with creatinine clearance. Increases in AUCs of about 42% in mild renal impairment (24 hr CrCl = 50 to 80 mL/min, Cockcroft-Gault [C-G]), about 56% in moderate renal impairment (24 hr CrCl = 30 to 50 mL/min, C-G), about 108% in severe renal impairment (24 hr CrCl ≤ 30 mL/min, C-G), and about 116% in ESRD subjects were observed, compared with healthy, age-matched control subjects.

The mean terminal half-life (t_1/2) was prolonged from 11.1 hours in the control subjects to approximately 13.5, 15.5, 17.6, and 22.8 hours in mild, moderate, severe renal impairment and ESRD subjects, respectively. Less than 5% of the drug in the body was cleared during a standard 4 hour hemodialysis procedure.

The maximum recommended dose in patients with moderate renal impairment is 50 mg per day. Dosage adjustment (50 mg every other day) is recommended in patients with severe renal impairment or ESRD [see Dosage and Administration (2.2) and Use in Specific Populations (8.6)].

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Desvenlafaxine succinate administered by oral gavage to mice and rats for 2 years did not increase the incidence of tumors in either study.

Mice received desvenlafaxine succinate at dosages up to 500/300 mg/kg/day (dosage lowered after 45 weeks of dosing). The 300 mg/kg/day dose is 15 times a human dose of 100 mg/day on a mg/m² basis.

Rats received desvenlafaxine succinate at dosages up to 300 mg/kg/day (males) or 500 mg/kg/day (females). The highest dose is 29 (males) or 48 (females) times a human dose of 100 mg/day on a mg/m² basis.

Mutagenesis

Desvenlafaxine was not mutagenic in the in vitro bacterial mutation assay (Ames test) and was not clastogenic in an in vitro chromosome aberration assay in cultured CHO cells, an in vivo mouse micronucleus assay, or an in vivo chromosome aberration assay in rats. Additionally, desvenlafaxine was not genotoxic in the in vitro CHO mammalian cell forward mutation assay and was negative in the in vitro BALB/c-3T3 mouse embryo cell transformation assay.

Impairment of fertility

When desvenlafaxine succinate was administered orally to male and female rats, fertility was reduced at the high dose of 300 mg/kg/day, which is 30 times a human dose of 100 mg/day (on a mg/m² basis).  There was no effect on fertility at 100 mg/kg/day, approximately 10 times a human dose of 100 mg/day (on a mg/m² basis).

14 CLINICAL STUDIES

The efficacy of desvenlafaxine extended-release tablets as a treatment for depression was established in four 8 week, randomized, double-blind, placebo-controlled, fixed-dose studies (at doses of 50 mg/day to 400 mg/day) in adult outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for major depressive disorder. In the first study, patients received 100 mg (n = 114), 200 mg (n = 116), or 400 mg (n = 113) of desvenlafaxine extended-release tablets once daily, or placebo (n = 118). In a second study, patients received either 200 mg (n = 121) or 400 mg (n = 124) of desvenlafaxine extended-release tablets once daily, or placebo (n = 124). In two additional studies, patients received 50 mg (n = 150 and n = 164) or 100 mg (n = 147 and n = 158) of desvenlafaxine extended-release tablets once daily, or placebo (n = 150 and n = 161).


Desvenlafaxine extended-release tablets showed superiority over placebo as measured by improvement in the 17-item Hamilton Rating Scale for Depression (HAM-D₁₇) total score in four studies and overall improvement, as measured by the Clinical Global Impressions Scale - Improvement (CGI-I), in three of the four studies. In studies directly comparing 50 mg/day and 100 mg/day there was no suggestion of a greater effect with the higher dose and adverse reactions and discontinuations were more frequent at higher doses [see Dosage and Administration (2.1)].

Table 8: Primary Efficacy (HAM-D₁₇) Results for Short-term Studies

			Desvenlafaxine Extended-Release Tablets
Study No.	Primary Endpoint: HAM-D17	Placebo	50 mg/day	100 mg/day	200 mg/day	400 mg/day
1	Baseline Score (SDStandard deviation)	23.1 (2.5)		23.2 (2.5)	22.9 (2.4)	23.0 (2.2)
	Difference from Placebo (95% CIDifference between least squares means at final evaluation, calculated as drug response minus placebo response; unadjusted 95% confidence intervals)			-2.9Adjusted p-value < 0.05 (-5.1, -0.8)	-2.0	-3.1Adjusted p-value < 0.05 (-5.2, -0.9)
2	Baseline Score (SDStandard deviation)	25.3 (3.3)			24.8 (2.9)	25.2 (3.2)
	Difference from Placebo (95% CIDifference between least squares means at final evaluation, calculated as drug response minus placebo response; unadjusted 95% confidence intervals)				-3.3Adjusted p-value < 0.05 (-5.3, -1.2)	-2.8Adjusted p-value < 0.05 (-4.8, -0.7)
3	Baseline Score (SDStandard deviation)	23.0 (2.6)	23.4 (2.6)	23.4 (2.6)
	Difference from Placebo (95% CIDifference between least squares means at final evaluation, calculated as drug response minus placebo response; unadjusted 95% confidence intervals)		-1.9Adjusted p-value < 0.05 (-3.5, -0.3)	-1.5
4	Baseline Score (SDStandard deviation)	24.3 (2.6)	24.3 (2.4)	24.4 (2.7)
	Difference from Placebo (95% CIDifference between least squares means at final evaluation, calculated as drug response minus placebo response; unadjusted 95% confidence intervals)		-2.5Adjusted p-value < 0.05 (-4.1, -0.9)	-3.0Adjusted p-value < 0.05 (-4.7, -1.4)

Analyses of the relationships between treatment outcome and age and treatment outcome and gender did not suggest any differential responsiveness on the basis of these patient characteristics. There was insufficient information to determine the effect of race on outcome in these studies.

16 HOW SUPPLIED/STORAGE AND HANDLING

Desvenlafaxine extended-release tablets are supplied as follows:

50 mg - light pink, circular, biconvex, beveled edge film-coated tablets, imprinted with ‘747’ in black ink on one side and plain on the other side. 
Bottles of 30’s with

Child Resistant Cap (unit of use)…………………..NDC 47335-747-83
Bottles of 90’s with Child Resistant Cap (unit of use)………………..…NDC 47335-747-81
Bottles of 1000’s with Non Child Resistant Cap……….…………………...NDC 47335-747-18

100 mg - brick red, circular biconvex, beveled edge, film-coated tablets, imprinted with ‘804’ in black ink on one side and plain on the other side.
Bottles of 30’s with Child Resistant Cap (unit of use)…………………..NDC 47335-804-83
Bottles of 90’s with Child Resistant Cap (unit of use)………………..…NDC 47335-804-81
Bottles of 1000’s with Non Child Resistant Cap……….…………………...NDC 47335-804-18

Store desvenlafaxine extended-release tablets at 20° to 25°C (68° to 77°F); excursions permitted between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature].

Each tablet contains 72 mg or 144 mg of desvenlafaxine fumarate equivalent to 50 mg or 100 mg of desvenlafaxine, respectively.

The unit-of-use package is intended to be dispensed as a unit.

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

17 PATIENT COUNSELING INFORMATION

See FDA-approved patient labeling (Medication Guide)
Advise patients, their families, and their caregivers about the benefits and risks associated with treatment with desvenlafaxine extended-release tablets and counsel them in their appropriate use.
Advise patients, their families, and their caregivers to read the Medication Guide and assist them in understanding its contents. The complete text of the Medication Guide is reprinted at the end of this document.
Suicide Risk
Advise patients, their families and caregivers to look for the emergence of suicidality, especially early during treatment and when the dose is adjusted up or down [see Boxed Warning and Warnings and Precautions (5.1)].

Concomitant Medication
Advise patients taking desvenlafaxine extended-release tablets not to use concomitantly other products containing desvenlafaxine or venlafaxine. Healthcare professionals should instruct patients not to take desvenlafaxine extended-release tablets with an MAOI or within 14 days of stopping an MAOI and to allow 7 days after stopping desvenlafaxine extended-release tablets before starting an MAOI [see Contraindications (4)].

Serotonin Syndrome

Caution patients about the risk of serotonin syndrome, particularly with the concomitant use of desvenlafaxine extended-release tablets with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort supplements) [see Warnings and Precautions (5.2)].

Elevated Blood Pressure

Advise patients that they should have regular monitoring of blood pressure when taking desvenlafaxine extended-release tablets [see Warnings and Precautions (5.3)].

Abnormal Bleeding

Patients should be cautioned about the concomitant use of desvenlafaxine extended-release tablets and NSAIDs, aspirin, warfarin, or other drugs that affect coagulation since combined use of psychotropic drugs that interfere with serotonin reuptake and these agents has been associated with an increased risk of bleeding [see Warnings and Precautions (5.4)].

Narrow-angle Glaucoma

Advise patients with raised intraocular pressure or those at risk of acute narrow-angle glaucoma (angle-closure glaucoma) that mydriasis has been reported and they should be monitored [see Warnings and Precautions (5.5)].

Activation of Mania/Hypomania

Advise patients, their families and caregivers to observe for signs of activation of mania/hypomania [see Warnings and Precautions ( 5.6)].

Discontinuation

Advise patients not to stop taking desvenlafaxine extended-release tablets without talking first with their healthcare professional. Patients should be aware that discontinuation effects may occur when stopping desvenlafaxine extended-release tablets [see Warnings and Precautions (5.7) and Adverse Reactions (6.1)].

Switching Patients From Other Antidepressants to Desvenlafaxine Extended-Release Tablets

Discontinuation symptoms have been reported when switching patients from other antidepressants, including venlafaxine, to desvenlafaxine extended-release tablets. Tapering of the initial antidepressant may be necessary to minimize discontinuation symptoms.

Interference with Cognitive and Motor Performance

Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that desvenlafaxine extended-release tablet therapy does not adversely affect their ability to engage in such activities.

Alcohol

Advise patients to avoid alcohol while taking desvenlafaxine extended-release tablets [see Drug Interactions (7.7)].

Allergic Reactions

Advise patients to notify their physician if they develop allergic phenomena such as rash, hives, swelling, or difficulty breathing.

Pregnancy

Advise patients to notify their physician if they become pregnant or intend to become pregnant during therapy [see Use in Specific Populations (8.1)].

Nursing

Advise patients to notify their physician if they are breastfeeding an infant [see Use in Specific Populations (8.3)].

Residual Inert Matrix Tablet

Patients receiving desvenlafaxine extended-release tablets may notice an inert matrix tablet passing in the stool or via colostomy. Patients should be informed that the active medication has already been absorbed by the time the patient sees the inert matrix tablet.

MEDICATION GUIDE

desvenlafaxine extended-release tablets
(des VEN la FAX een)
 

Read this Medication Guide before you start taking desvenlafaxine extended-release tablets and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.

What is the most important information I should know about desvenlafaxine extended-release tablets?
Desvenlafaxine extended-release tablets and other antidepressant medicines may cause serious side effects.

• Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment.
• Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) bipolar illness (also called manic-depressive illness) or suicidal thoughts or actions.
• How can I watch for and try to prevent suicidal thoughts and actions?

• Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.
• Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.
• Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms.

Call a healthcare provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you:

• thoughts about suicide or dying     
• trouble sleeping (insomnia)
• attempts to commit suicide             
• new or worse irritability
• new or worse depression                  
• acting aggressive, being angry, or violent
• new or worse anxiety                        
• acting on dangerous impulses
• feeling very agitated or restless      
• an extreme increase in activity and talking (mania)
• panic attacks     
• other unusual changes in behavior or mood 

What are desvenlafaxine extended-release tablets?

Desvenlafaxine extended-release tablets are a prescription medicine used to treat Major Depressive Disorder (MDD). Desvenlafaxine extended-release tablets belong to a class of medicines known as SNRIs (or serotonin-norepinephrine reuptake inhibitors).

Who should not take desvenlafaxine extended-release tablets?
Do not take desvenlafaxine extended-release tablets if you:

• are allergic to desvenlafaxine, venlafaxine or any of the ingredients in desvenlafaxine extended-release tablets. See the end of this Medication Guide for a complete list of ingredients in desvenlafaxine extended-release tablets.
• take a monoamine oxidase inhibitor (MAOI). Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid and the intravenous medicine methylene blue.
• have taken an MAOI within 7 days of stopping desvenlafaxine extended-release tablets unless directed by your healthcare provider.
• have started desvenlafaxine extended-release tablets and if you stopped taking an MAOI in the last 14 days unless directed by your healthcare provider.

What should I tell my healthcare provider before taking desvenlafaxine extended-release tablets?
Before you take desvenlafaxine extended-release tablets, tell your healthcare provider about all your medical conditions, including if you:

• have high blood pressure
• have heart problems
• have high cholesterol or high triglycerides
• have a history of a stroke
• have or had depression, suicidal thoughts or behavior
• have glaucoma
• have kidney problems
• have liver problems
• have or had bleeding problems
• have or had seizures or convulsions
• have mania or bipolar disorder
• have low sodium levels in your blood
• are pregnant or plan to become pregnant. It is not known if desvenlafaxine extended-release tablets will harm your unborn baby.
• are breastfeeding or plan to breastfeed. Desvenlafaxine extended-release tablets can pass into your breast milk and may harm your baby. Talk with your healthcare provider about the best way to feed your baby if you take desvenlafaxine extended-release tablets.

Tell your healthcare provider about all the medicines that you take,including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Serotonin syndrome

A rare, but potentially life-threatening condition called serotonin syndrome can happen when medicines such as desvenlafaxine extended-release tablets are taken with certain other medicines. Serotonin syndrome can cause serious changes in how your brain, muscles, heart and blood vessels, and digestive system work.

Especially tell your healthcare provider if you take the following:

• medicines to treat migraine headaches known as triptans
• medicines used to treat mood, anxiety, psychotic, or thought disorders, including tricyclics, lithium, selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), or other dopamine antagonists, such as metoclopramide
• sibutramine
• tramadol
• St. John’s Wort
• MAOIs (including linezolid, an antibiotic and intravenous methylene blue)
• tryptophan supplements

Ask your healthcare provider if you are not sure if you are taking any of these medicines.
Before you take desvenlafaxine extended-release tablets with any of these medicines, talk to your healthcare provider about serotonin syndrome. See “What are the possible side effects of desvenlafaxine extended-release tablets?”
Do not take desvenlafaxine extended-release tablets with other medicines containing desvenlafaxine or venlafaxine.
Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

How should I take desvenlafaxine extended-release tablets?

• Take desvenlafaxine extended-release tablets exactly as your healthcare provider has told you.
• Take desvenlafaxine extended-release tablets at about the same time each day.
• Desvenlafaxine extended-release tablets may be taken either with or without food.
• Swallow desvenlafaxine extended-release tablets whole, with fluid. Do not crush, cut, chew, or dissolve desvenlafaxine extended-release tablets because the tablets are time-released.
• When you take desvenlafaxine extended-release tablets, you may see something in your stool that looks like a tablet. This is the empty shell from the tablet after the medicine has been absorbed by your body.
• It is common for antidepressant medicines such as desvenlafaxine extended-release tablets to take several weeks before you start to feel better. Do not stop taking desvenlafaxine extended-release tablets if you do not feel results right away.
• Do not stop taking or change the dose of desvenlafaxine extended-release tablets without talking with your healthcare provider, even if you feel better.
• Talk with your healthcare provider about how long you should use desvenlafaxine extended-release tablets. Take desvenlafaxine extended-release tablets for as long as your healthcare provider tells you to.
• If you miss a dose of desvenlafaxine extended-release tablets, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not try to “make up” for the missed dose by taking two doses at the same time.
• Do not take more desvenlafaxine extended-release tablets than prescribed by your healthcare provider. If you take more desvenlafaxine extended-release tablets than the amount prescribed, contact your healthcare provider right away.
• If you take too many desvenlafaxine extended-release tablets, call the Poison Control Center at 1-800-222-1222 or go to the nearest hospital emergency room right away.

Switching from other antidepressants
Side effects from discontinuing antidepressant medication have occurred when patients switched from other antidepressants, including venlafaxine, to desvenlafaxine extended-release tablets. Your healthcare provider may gradually reduce the dose of your initial antidepressant medication to help to reduce these side effects.

What should I avoid while taking desvenlafaxine

extended-release tablets?

• Do not drive a car or operate machinery until you know how desvenlafaxine extended-release tablets affect you.
• Avoid drinking alcohol while taking desvenlafaxine extended-release tablets.

What are the possible side effects of desvenlafaxine extended-release tablets?
Desvenlafaxine extended-release tablets can cause serious side effects, including:

• See “What is the most important information I should know about desvenlafaxine extended-release tablets?”
• Serotonin syndrome. See “What should I tell my healthcare provider before taking desvenlafaxine extended-release tablets?” 

Get medical help right away if you think that you have these syndromes. Signs and symptoms of these syndromes may include:

• restlessness    
• increase in blood pressure
• hallucinations (seeing and   
• hearing things that are not real) 
• diarrhea
• loss of coordination  
• coma
• fast heart beat   
• nausea
• increased body temperature  
• vomiting
• muscle stiffness 
• confusion

Desvenlafaxine extended-release tablets may also cause other serious side effects, including:

• New or worsened high blood pressure (hypertension). Your healthcare provider should monitor your blood pressure before and while you are taking desvenlafaxine extended-release tablets. If you have high blood pressure, it should be controlled before you start taking desvenlafaxine extended-release tablets.
• Abnormal bleeding or bruising. Desvenlafaxine extended-release tablets and other SNRIs/SSRIs may cause you to have an increased chance of bleeding. Taking aspirin, NSAIDs (non-steroidal anti-inflammatory drugs), or blood thinners may add to this risk. Tell your healthcare provider right away about any unusual bleeding or bruising.
• Glaucoma (increased eye pressure)
• Mania or hypomania (manic behavior)
• Symptoms when stopping desvenlafaxine extended-release tablets (discontinuation symptoms). Side effects may occur when stopping desvenlafaxine extended-release tablets (discontinuation symptoms), especially when therapy is stopped suddenly. Your healthcare provider may want to decrease your dose slowly to help avoid side effects. Some of these side effects may include:
  • headache        
  • tiredness
  • dizziness         
  • anxiety
  • nausea           
  • abnormal dreams
  • irritability              
  • sweating
  • sleeping problems (insomnia)             
  • diarrhea

• 
  Seizures (convulsions)
• 
  Low sodium levels in your blood. Symptoms of this may include: headache, difficulty concentrating, memory changes, confusion, weakness and unsteadiness on your feet. In severe or more sudden cases, symptoms can include: hallucinations (seeing or hearing things that are not real), fainting, seizures and coma. If not treated, severe low sodium levels could be fatal.
• 
  Lung problems. Some people who have taken the medicine venlafaxine which is the same kind of medicine as the medicine in desvenlafaxine extended-release tablets have had lung problems. Symptoms of lung problems include difficulty breathing, cough, or chest discomfort. Tell your healthcare provider right away if you have any of these symptoms.

Common side effects of desvenlafaxine extended-release tablets include:

• nausea
• dizziness
• insomnia
• sweating
• constipation
• sleepiness
• loss of appetite
• anxiety
• decreased sex drive
• delayed orgasm and ejaculation

These are not all the possible side effects of desvenlafaxine extended-release tablets. Tell your healthcare provider about any side effect that bothers you or does not go away.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store desvenlafaxine extended-release tablets?

• 
  Store desvenlafaxine extended-release tablets between 68° to 77°F (20° to 25°C).
• 
  Do not use desvenlafaxine extended-release tablets after the expiration date (EXP), which is on the container. The expiration date refers to the last day of that month.

Keep desvenlafaxine extended-release tablets and all medicines out of the reach of children.
General Information about the safe and effective use of desvenlafaxine extended-release tablets.
Medicines are sometimes used for purposes other than those listed in a Medication Guide. Do not use desvenlafaxine extended-release tablets for a condition for which it was not prescribed. Do not give desvenlafaxine extended-release tablets to other people, even if they have the same symptoms that you have. It may harm them.


This Medication Guide summarizes the most important information about desvenlafaxine extended-release tablets. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about desvenlafaxine extended-release tablets that is written for healthcare professionals.
For more information call 1-800-818-4555.

What are the ingredients in desvenlafaxine extended-release tablets?
Active ingredient: desvenlafaxine
Inactive ingredients:   hypromellose, microcrystalline cellulose, talc, magnesium stearate, colloidal silicon dioxide and film coating, which consists of hypromellose, titanium dioxide, polyethylene glycol, talc and iron oxides.  Additionally, the 50 mg tablet contains ferric oxide red.
The imprinting ink contains shellac, black iron oxide, n-butyl alcohol, propylene glycol and ammonium hydroxide.
This Medication Guide has been approved by the U.S. Food and Drug Administration.


Distributed by:
Caraco Pharmaceutical Laboratories, Ltd.
1150 Elijah McCoy Drive, Detroit, MI 48202

Manufactured by:
Sun Pharmaceutical Ind. Ltd.
Halol-Baroda Highway,
Halol-389 350, Gujarat, India.

PJPI0429C
Revised: 01/2014

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 47335-747-83
Rx only
Desvenlafaxine Extended-Release Tablets
50 mg
30 Tablets
Unit of Use
PHARMACIST: Dispense the accompanying Medication Guide to each patient 

NDC 47335-804-83
Rx only
Desvenlafaxine Extended-Release Tablets
100 mg
30 Tablets
Unit of Use
PHARMACIST: Dispense the accompanying Medication Guide to each patient

Desvenlafaxine Desvenlafaxine TABLET, EXTENDED RELEASE Product Information Product Type Human prescription drug label Item Code (Source) NDC:47335-747 Route of Administration ORAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength DESVENLAFAXINE FUMARATE MONOHYDRATE DESVENLAFAXINE 50 mg Inactive Ingredients Ingredient Name Strength cellulose, microcrystalline HYPROMELLOSES MAGNESIUM STEARATE talc SILICON DIOXIDE ferric oxide red titanium dioxide POLYETHYLENE GLYCOLS FERRIC OXIDE YELLOW SHELLAC FERROSOFERRIC OXIDE BUTYL ALCOHOL propylene glycol AMMONIA Product Characteristics Color Size Imprint Code Shape PINK (light pink) 11 mm 747 ROUND Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:47335-747-83 30 in 1 BOTTLE 2 NDC:47335-747-81 90 in 1 BOTTLE 3 NDC:47335-747-18 1000 in 1 BOTTLE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA205583 2014-01-30

Desvenlafaxine Desvenlafaxine TABLET, EXTENDED RELEASE Product Information Product Type Human prescription drug label Item Code (Source) NDC:47335-804 Route of Administration ORAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength DESVENLAFAXINE FUMARATE MONOHYDRATE DESVENLAFAXINE 100 mg Inactive Ingredients Ingredient Name Strength cellulose, microcrystalline HYPROMELLOSES MAGNESIUM STEARATE talc SILICON DIOXIDE ferric oxide red titanium dioxide POLYETHYLENE GLYCOLS FERRIC OXIDE YELLOW SHELLAC FERROSOFERRIC OXIDE BUTYL ALCOHOL propylene glycol AMMONIA Product Characteristics Color Size Imprint Code Shape RED (Brick red) 11 mm 804 ROUND Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:47335-804-83 30 in 1 BOTTLE 2 NDC:47335-804-81 90 in 1 BOTTLE 3 NDC:47335-804-18 1000 in 1 BOTTLE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA205583 2014-01-30